~15 spots leftby Apr 2026

Open-label Extension Study Of RN624

Recruiting in Palo Alto (17 mi)
+35 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Pfizer
No Placebo Group
Prior Safety Data

Trial Summary

What is the purpose of this trial?

Study RN624-CL007 is planned to be an open-label protocol to enroll subjects who have previously participated in Study No. RN624-CL006. In this study, subjects will receive RN624 on an open-label basis.

Eligibility Criteria

Inclusion Criteria

Enrolled in Study RN624-CL006

Treatment Details

Interventions

  • RN624 (Monoclonal Antibodies)
Participant Groups
1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment1 Intervention

Find a Clinic Near You

Research Locations NearbySelect from list below to view details:
The Center for Rheumatology and Bone ResearchWheaton, MD
Pharmacotherapy Research Associates IncorporatedZanesville, OH
New Orleans Center for Clinical ResearchKnoxville, TN
Radiant Research - San AntonioSan Antonio, TX
More Trial Locations
Loading ...

Who Is Running the Clinical Trial?

PfizerLead Sponsor

References